COMMUNIQUÉS West-GlobeNewswire

Achieve Life Sciences to Announce First Quarter Financial Results and Host Conference Call and Webcast on May 9, 2024
25/04/2024
SEATTLE and VANCOUVER, British Columbia, April 25, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of [...]
iSpecimen to Report First Quarter 2024 Financial Results on May 7, 2024
25/04/2024
LEXINGTON, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”) , an online global marketplace that connects scientists requiring biospecimens for medical research with [...]
MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences
25/04/2024
Oral presentations include additional comparative data between EscharEx ® and SANTYL ® , and new analyses show strong correlation between wound bed preparation and wound healing Analyses validate the planned design and [...]
Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated
25/04/2024
CTX-009, the Company’s bispecific DLL4/VEGF-A antibody, in combination with paclitaxel, has shown promising clinical responses in patients with advanced biliary tract cancer (BTC) in its Phase 2 study Top-line data [...]
Sensus Healthcare Issues Reminder That its First Quarter 2024 Financial Results and Business Update Conference Call Will be Held on Thursday, May 9, 2024
25/04/2024
BOCA RATON, Fla., April 25, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological [...]
BioStem Technologies to Present at the 2024 Planet MicroCap Showcase
25/04/2024
BioStem CEO, Jason Matuszewski, will present on Wednesday, May 1, 2024 at 11.30 am PST POMPANO BEACH, Fla., April 25, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine [...]
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
25/04/2024
XOMA is entitled to a mid-single digit royalty on global OJEMDA™ sales First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF [...]
Kura Oncology to Report First Quarter 2024 Financial Results
25/04/2024
SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today [...]
Jushi Holdings Inc. to Report First Quarter 2024 Financial Results on May 9, 2024
25/04/2024
BOCA RATON, Fla., April 25, 2024 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF) , a vertically integrated, multi-state cannabis operator, announced that it expects to [...]
Streamline Health® Signs Second Enterprise Client
25/04/2024
700-Bed health system adds eValuator ™ , becomes second healthcare provider leveraging both eValuator and RevID to improve revenue integrity pre-bill Atlanta, GA, April 25, 2024 (GLOBE NEWSWIRE) -- Streamline Health [...]
HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab
25/04/2024
Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or metastatic OPSCC aligned with FDA feedback HB-200 accepted for [...]
Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi™ and Clobetasol Propionate Ophthalmic Suspension
25/04/2024
Company announces results from a Phase IV study of Mydcombi designed to characterize the efficacy and duration of the lowest deliverable dose (one 8µL spray per eye) Also announces upcoming ARVO presentation on the [...]
Sweetwater Brewing Unveils Modern Rebrand
25/04/2024
The Brewery’s New Look Marks a New Era for the Craft Beer Brand ATLANTA, April 25, 2024 (GLOBE NEWSWIRE) -- SweetWater Brewing Company (“SweetWater Brewing” or “SweetWater”), the largest craft brewer in the Southeast [...]
Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million
25/04/2024
Conference Call and Webcast to be held April 25, 2024, at 10:00 a.m. Eastern Time YARDLEY, Pa., April 25, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, [...]
BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024
25/04/2024
NEW HAVEN, Conn., April 25, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and [...]
Nucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes Scientific Advisory Board of world-leading experts
25/04/2024
Nucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes Scientific Advisory Board of world-leading experts John Davis brings direct clinical expertise as Nucleome advances [...]
Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases
25/04/2024
Mammoth’s proprietary ultracompact CRISPR-based gene editing platform and Regeneron’s proprietary delivery technologies set to advance in vivo programs in multiple tissue and cell types Mammoth to receive $100 million [...]
Microbix Collaborator Introduces New Lab Accreditation Program
25/04/2024
Microbix Product Supporting Testing for Drug-Resistant Sexually-Transmitted Infection MISSISSAUGA, Ontario, April 25, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. ( TSX: MBX, OTCQX: MBXBF, Microbix ® ), a life [...]
TELA Bio to Announce First Quarter 2024 Financial Results
25/04/2024
MALVERN, Pa., April 25, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today [...]

Pages